Example：10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Additional points to consider before incorporating the Food and Drug Administration-approved therapies for systemic sclerosis-associated interstitial lung disease Arthritis & Rheumatology (IF10.995), Pub Date : 2021-10-05, DOI: 10.1002/art.41993 Markus Bredemeier
We congratulate the authors for the excellent review, not only restricted to recently approved therapies, on the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) (1). However, it is our opinion that some aspects that currently affect our medical practice merit further commentary.